Table 4 Multivariable determinants of outcome in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial (odds of experiencing a skeletal-related event during the first 12Â months)
From: The use of randomisation-based efficacy estimators in non-inferiority trials
Variable | Adjusted odds ratio | 95% Confidence interval | p value | |
|---|---|---|---|---|
Lower | Upper | |||
Gender (female compared to male) | 0.23 | 0.06 | 0.88 | 0.032 |
18.5 kg/m2 < BMI ≤ 25 kg/m2 (normal/healthy weight) compared to ≤ 18.5 kg/m2 (underweight) | 6.16 | 0.75 | 50.65 | <0.001 |
25 kg/m2 < BMI ≤ 30 kg/m2 (overweight) compared to ≤ 18.5 kg/m2 (underweight) | 6.85 | 0.84 | 56.13 | |
30 kg/m2 < BMI ≤ 35 kg/m2 (moderately obese) compared to ≤ 18.5 kg/m2 (underweight) | 13.17 | 1.59 | 108.81 | |
35 kg/m2 < BMI ≤ 40 kg/m2 (severely obese) compared to ≤ 18.5 kg/m2 (underweight) | 6.99 | 0.81 | 60.39 | |
BMI > 40 kg/m2 (very severely obese) compared to ≤ 18.5 kg/m2 (underweight) | 13.11 | 1.44 | 119.65 | |
QLQ-C30 global health domain (per unit increase) | 0.98 | 0.98 | 0.99 | 0.001 |
QLQ-C30 role functioning domain (per unit increase) | 1.01 | 1.00 | 1.02 | 0.005 |
QLQ-C30 nausea / vomiting domain (per unit increase) | 1.01 | 1.01 | 1.02 | <0.001 |
QLQ-C30 dyspnoea domain (per unit increase) | 0.99 | 0.99 | 1.00 | 0.056 |
SRE within the three months prior to baseline compared to no SRE within three months prior to baseline | 1.56 | 1.14 | 2.13 | 0.006 |
Recent use of pain medication at baseline compared to no recent use of pain medication | 1.63 | 1.08 | 2.46 | 0.019 |